Many Americans have pre-diabetes and should be considered for metformin therapy

Diabetes Care

Volumn 33, Issue 1, 2010, Pages 49-54

  Rhee, Mary K ^a   Herrick, Kirsten ^b   Ziemer, David C ^a   Vaccarino, Viola ^c   Weintraub, William S ^d   Venkat Narayan, K M ^a,c   Kolm, Paul ^d   Twombly, Jennifer G ^a   Phillips, Lawrence S ^a,e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

^d CHRISTIANA CARE HEALTH SYSTEM   (United States)

^e ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY MASS; CAUCASIAN; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; RISK ASSESSMENT; RISK FACTOR; SCREENING;

CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PREDIABETIC STATE; RISK FACTORS; UNITED STATES;

EID: 74249111367     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-0341     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA, U.S. Department of Health and Human Services, 2008
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
3. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, Geiss LS. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009;32:287-294
4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
5. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077
6. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105
7. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34:877-890
8. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-759
9. Phillips LS, Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Chatterjee R, Narayan KM, Koch DD. Glucose challenge test screening for prediabetes and undiagnosed diabetes. Diabetologia 2009;52:1798-1807
10. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III. Hyattsville, MD, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2009. Available from http://www.cdc.gov/ nchs/nhanes/nh3data.htm. Accessed 4 August 2009
11. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Continuous National Health and Nutrition Examination Survey, NHANES 2005-2006. Hyattsville, MD, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available from http://www.cdc.gov/ nchs/nhanes/nhanes2005-2006/nhanes05-06.htm. Accessed 4 August 2009
12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752
13. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005;146:693-700
14. Warram JH, Sigal RJ, Martin BC, Krolewski AS, Soeldner JS. Natural history of impaired glucose tolerance: follow-up at Joslin Clinic. Diabet Med 1996;13:S40-S45
15. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes 2003;52:1475-1484
16. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-2144
17. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria: collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617-621
18. Barr EL, Wong TY, Tapp RJ, Harper CA, Zimmet PZ, Atkins R, Shaw JE. Is peripheral neuropathy associated with retinopathy and albuminuria in individuals with impaired glucose metabolism? The 1999-2000 AusDiab. Diabetes Care 2006;29:1114-1116
19. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161
20. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008;19:129-137
21. Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 2003;115(Suppl. 8A):111S-115S
22. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-1136
23. American College of Endocrinology Task Force on Pre-Diabetes. American College of Endocrinology Consensus Statement on the Diagnosis and Management of Pre-Diabetes in the Continuum of Hyperglycemia - When Do the Risks of Diabetes Begin? Washington, DC, American College of Endocrinology Task Force on Pre-Diabetes, 2008
24. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE, the Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-332